---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-079678"
form_type: "8-K"
ticker: "DMAA"
cik: "0002028614"
company_name: "Drugs Made In America Acquisition Corp."
filed_at: "2026-07-20T21:00:13+00:00"
generated_at: "2026-07-20T21:02:11.668218+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# DMAA amends PAGC merger: sponsor forfeits 50% founder shares, rights buyback $0.25-$0.35, potential three-party deal

## Summary
- Sponsor to forfeit at least 50% of founder shares; remainder subject to earnout at $12.50/$15.00; 430K private placement rights surrendered.
- Company to commence tender offer for rights at $0.25-$0.35 per right, funded from non-trust sources; rights not tendered remain outstanding.
- Merger consideration recalculated based on fully diluted shares outstanding; minimum cash target $30M, floor $15M.
- Parties in negotiations for potential three-party business combination; contingent Amendment No. 4 pre-approved, effective if LOI signed by Sept 30, 2026.
- Related-party protections: independent fairness opinion required; independent directors to make certain determinations.

## SEC filing metadata
- accession: 0001213900-26-079678
- form_type: 8-K
- ticker: DMAA
- cik: 0002028614
- company_name: Drugs Made In America Acquisition Corp.
- filed_at: 2026-07-20T21:00:13+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2028614/000121390026079678/0001213900-26-079678-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2028614/000121390026079678/ea0298461-8k425_drugs.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-079678
- JSON: https://secwatch.observer/filing/0001213900-26-079678.json
- Plain text: https://secwatch.observer/filing/0001213900-26-079678.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.